ESC Premium Access

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON

Congress Presentation

About the speaker

Professor Adriaan Voors

University Medical Centre Groningen, Groningen (Netherlands (The))
76 presentations
1 follower

7 more presentations in this session

Opening question.

Thumbnail

Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

Speaker: Professor G. Filippatos (Athens, GR)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO

Speaker: Professor M. Packer (Dallas, US)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON

Speaker: Professor A. Voors (Groningen, NL)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

Speaker: Professor M. Packer (Dallas, US)

Thumbnail

Access the full session

First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Speakers: Professor A. Voors, Professor G. Filippatos, Professor M. Packer, Professor A. Voors, Professor M. Packer
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb